JP7809344B2 - 新規遺伝子組換えワクシニアウイルス及びその利用 - Google Patents

新規遺伝子組換えワクシニアウイルス及びその利用

Info

Publication number
JP7809344B2
JP7809344B2 JP2022563731A JP2022563731A JP7809344B2 JP 7809344 B2 JP7809344 B2 JP 7809344B2 JP 2022563731 A JP2022563731 A JP 2022563731A JP 2022563731 A JP2022563731 A JP 2022563731A JP 7809344 B2 JP7809344 B2 JP 7809344B2
Authority
JP
Japan
Prior art keywords
gene
vaccinia virus
genes
combination
ccl21
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022563731A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022107705A1 (https=
Inventor
貴史 中村
恵美 脇水
大夢 中武
創 黒▲崎▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tottori University NUC
Original Assignee
Tottori University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tottori University NUC filed Critical Tottori University NUC
Publication of JPWO2022107705A1 publication Critical patent/JPWO2022107705A1/ja
Priority to JP2025167868A priority Critical patent/JP2025188115A/ja
Application granted granted Critical
Publication of JP7809344B2 publication Critical patent/JP7809344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022563731A 2020-11-17 2021-11-15 新規遺伝子組換えワクシニアウイルス及びその利用 Active JP7809344B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025167868A JP2025188115A (ja) 2020-11-17 2025-10-06 新規遺伝子組換えワクシニアウイルス及びその利用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020191128 2020-11-17
JP2020191128 2020-11-17
PCT/JP2021/041825 WO2022107705A1 (ja) 2020-11-17 2021-11-15 新規遺伝子組換えワクシニアウイルス及びその利用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025167868A Division JP2025188115A (ja) 2020-11-17 2025-10-06 新規遺伝子組換えワクシニアウイルス及びその利用

Publications (2)

Publication Number Publication Date
JPWO2022107705A1 JPWO2022107705A1 (https=) 2022-05-27
JP7809344B2 true JP7809344B2 (ja) 2026-02-02

Family

ID=81708035

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563731A Active JP7809344B2 (ja) 2020-11-17 2021-11-15 新規遺伝子組換えワクシニアウイルス及びその利用
JP2025167868A Pending JP2025188115A (ja) 2020-11-17 2025-10-06 新規遺伝子組換えワクシニアウイルス及びその利用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025167868A Pending JP2025188115A (ja) 2020-11-17 2025-10-06 新規遺伝子組換えワクシニアウイルス及びその利用

Country Status (6)

Country Link
US (1) US20230355691A1 (https=)
EP (1) EP4249596A4 (https=)
JP (2) JP7809344B2 (https=)
CN (1) CN116322727A (https=)
CA (1) CA3196813A1 (https=)
WO (1) WO2022107705A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025524372A (ja) * 2022-06-10 2025-07-30 バクシネックス インコーポレーティッド 複合膜抗原に特異的な抗体を選択するための方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506974A (ja) 2002-08-12 2006-03-02 デイビッド キルン ポックスウイルスおよび癌に関する方法および組成物
WO2013038066A1 (en) 2011-09-16 2013-03-21 Oncos Therapeutics Ltd. Modified oncolytic vaccinia virus
WO2016008976A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
WO2016076441A1 (ja) 2014-11-11 2016-05-19 公益財団法人東京都医学総合研究所 Ｃ型肝炎の治療及び／又は予防用医薬組成物
WO2018012570A1 (ja) 2016-07-13 2018-01-18 国立大学法人鳥取大学 外来遺伝子発現ワクシニアウイルスの製造方法
WO2019134049A1 (en) 2018-01-05 2019-07-11 Bell John C Modified vaccinia vectors
WO2019143201A1 (ko) 2018-01-19 2019-07-25 코오롱생명과학 주식회사 재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물
WO2020067085A1 (ja) 2018-09-26 2020-04-02 アステラス製薬株式会社 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863542A (en) 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
DE69519521T2 (de) 1994-10-03 2001-06-28 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
WO2000073479A1 (en) 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
EP1549672B1 (en) 2002-05-03 2010-09-01 Mayo Foundation For Medical Education And Research Ablated slam-dependent cell entry
WO2005007824A2 (en) 2003-07-08 2005-01-27 Arizona Board Of Regents Mutants of vaccinia virus as oncolytic agents
WO2005054451A1 (ja) 2003-12-05 2005-06-16 Hokkaido Technology Licensing Office Co., Ltd. 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
US20130071430A1 (en) * 2010-04-09 2013-03-21 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
CN110527670A (zh) 2013-11-21 2019-12-03 国立大学法人鸟取大学 丝裂原活化蛋白激酶依赖性重组痘苗病毒(md-rvv)及其应用
WO2017014296A1 (ja) 2015-07-22 2017-01-26 国立大学法人鳥取大学 ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子
JP2019091609A (ja) 2017-11-14 2019-06-13 住友電装株式会社 コネクタ
AU2019359890B2 (en) * 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US20220056481A1 (en) * 2018-12-28 2022-02-24 Transgene M2-defective poxvirus
JP7737141B2 (ja) * 2019-05-14 2025-09-10 国立大学法人鳥取大学 細胞融合を誘導するワクシニアウイルス及びその利用
JP6996596B2 (ja) 2020-08-11 2022-01-17 ブラザー工業株式会社 情報処理プログラム、情報処理装置、および情報処理装置の制御方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506974A (ja) 2002-08-12 2006-03-02 デイビッド キルン ポックスウイルスおよび癌に関する方法および組成物
WO2013038066A1 (en) 2011-09-16 2013-03-21 Oncos Therapeutics Ltd. Modified oncolytic vaccinia virus
WO2016008976A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
WO2016076441A1 (ja) 2014-11-11 2016-05-19 公益財団法人東京都医学総合研究所 Ｃ型肝炎の治療及び／又は予防用医薬組成物
WO2018012570A1 (ja) 2016-07-13 2018-01-18 国立大学法人鳥取大学 外来遺伝子発現ワクシニアウイルスの製造方法
WO2019134049A1 (en) 2018-01-05 2019-07-11 Bell John C Modified vaccinia vectors
WO2019143201A1 (ko) 2018-01-19 2019-07-25 코오롱생명과학 주식회사 재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물
WO2020067085A1 (ja) 2018-09-26 2020-04-02 アステラス製薬株式会社 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Cancer Immunology, Immunotherapy，2018年，Vol.67，pp.1853-1862，https://doi.org/10.1007/s00262-018-2236-7
Journal of Translational Medicine，2012年，Vol.10:9，pp.1-15，http://www.translational-medicine.com/content/10/1/9
JOURNAL OF VIROLOGY，2007年，Vol.81, No.12，pp.6286-6293，doi:10.1128/JVI.00274-07
Molecular Therapy，2020年04月28日，Vol.28, No.4S1，pp.589-590
Molecular Therapy: Oncolytics，2019年，Vol.15，pp.234-247，https://doi.org/10.1016/j.omto.2019.10.007.

Also Published As

Publication number Publication date
WO2022107705A1 (ja) 2022-05-27
EP4249596A4 (en) 2025-03-12
US20230355691A1 (en) 2023-11-09
JPWO2022107705A1 (https=) 2022-05-27
EP4249596A1 (en) 2023-09-27
CN116322727A (zh) 2023-06-23
CA3196813A1 (en) 2022-05-27
JP2025188115A (ja) 2025-12-25

Similar Documents

Publication Publication Date Title
JP6794442B2 (ja) 新規な遺伝子組換えワクシニアウイルス
KR102409147B1 (ko) 종양분해성 백시니아 바이러스
TW201945542A (zh) 重組溶瘤病毒組合物及其用途
CN105765062A (zh) 丝裂原活化蛋白激酶依赖性重组痘苗病毒（md-rvv）及其应用
JP7737141B2 (ja) 細胞融合を誘導するワクシニアウイルス及びその利用
JP2025188115A (ja) 新規遺伝子組換えワクシニアウイルス及びその利用
US11344589B2 (en) Genetically engineered vaccinia viruses
JP6731646B2 (ja) 外来遺伝子発現ワクシニアウイルスの製造方法
CN106413726A (zh) 痘病毒溶瘤载体
JP6915792B1 (ja) 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス
Shakiba et al. Comparison of the oncolytic activity of recombinant vaccinia virus strains LIVP-RFP and MVA-RFP against solid tumors
JP7699838B2 (ja) マイクロｒｎａで調節及び制御可能な単離された組換え腫瘍溶解性ポックスウイルス及びその使用
WO2021029385A1 (ja) 腫瘍溶解性ワクシニアウイルス
HK40056184B (zh) 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
CA3192853A1 (en) Mutant orf viruses and uses thereof
JP2019097564A (ja) Ｓｃｒ欠失ワクシニアウイルス

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260114

R150 Certificate of patent or registration of utility model

Ref document number: 7809344

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150